• BMX-IN-1: Selective BMX Kinase Inhibitor for Cancer & Infect

  2026-05-13

  BMX-IN-1 is a highly selective, irreversible BMX kinase inhibitor with demonstrated efficacy in inducing cell cycle arrest and apoptosis in cancer models. Recent evidence highlights its utility in probing host-pathogen interactions, specifically the modulation of lysosomal acidification by BMX in Mycobacterium tuberculosis infection. This dossier outlines the molecular rationale, benchmarks, and workflow integration for BMX-IN-1 in translational research.

• Zosuquidar (LY335979) 3HCl: Precision P-gp Inhibition in MDR

  2026-05-12

  Zosuquidar (LY335979) 3HCl enables robust reversal of multidrug resistance in cancer models by selectively inhibiting P-glycoprotein efflux activity. This guide translates the latest pharmacokinetic and workflow insights into actionable strategies for enhancing assay fidelity and chemotherapeutic sensitivity.

• Sodium dicloxacillin monohydrate: Precision in MSSA Research

  2026-05-12

  Sodium dicloxacillin monohydrate offers reproducible, strain-specific inhibition of methicillin-sensitive Staphylococcus aureus (MSSA), supporting both in vitro and in vivo Gram-positive bacterial infection research. This article presents actionable workflows and troubleshooting insights, translating key reference innovations into tangible bench advantages for APExBIO users.

• HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L): Technical Use Gu

  2026-05-11

  HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody enables sensitive fluorescent detection of rabbit primary antibodies for immunofluorescence, flow cytometry, and related assays. It is not intended for detection of non-rabbit antibodies or for protocols sensitive to glycerol or sodium azide.

• ERK5 and ERK1/2 in Vitamin D3-Induced AML Differentiation

  2026-05-11

  This study clarifies the distinct roles of ERK5 and ERK1/2 MAPK pathways in 1α,25-dihydroxyvitamin D3-induced terminal differentiation of myeloid leukemia cells. By dissecting how selective inhibition of these kinases influences cell cycle arrest and differentiation markers, the research advances understanding critical for developing more effective AML combination therapies.

• AI-Derived Prognostic Signature Enhances HCC Risk Stratifica

  2026-05-10

  This large-scale, multi-center study introduces a consensus artificial intelligence-driven prognostic signature (CAIPS) that integrates multi-omics and machine learning for improved prognosis and therapeutic guidance in hepatocellular carcinoma (HCC). The findings demonstrate CAIPS outperforms traditional models, identifies actionable drug candidates, and establishes a framework for personalized HCC management.

• Vernakalant Hydrochloride: Rapid AF Conversion and Atrial Se

  2026-05-09

  Vernakalant Hydrochloride (RSD1235) is an atrial-selective antiarrhythmic agent offering rapid conversion of atrial fibrillation (AF) with high efficacy and minimal ventricular impact. Clinical data confirm a 51.7% conversion rate for short-duration AF and a favorable safety profile. This article details its mechanism, benchmarks, and best practices for laboratory and clinical workflows.

• X-Gal: Mechanistic Precision and Strategic Guidance for Tran

  2026-05-08

  Explore how X-Gal (5-bromo-4-chloro-indolyl-β-D-galactopyranoside) enables molecular precision in blue-white colony screening and β-galactosidase assays, informed by translational advances in sensory biology. This thought-leadership article synthesizes mechanistic insight, competitive product intelligence, and actionable workflow recommendations, guiding researchers to optimize experimental outcomes and anticipate future applications.

• Clozapine: Atypical Antipsychotic Mechanisms & Research Prot

  2026-05-08

  Clozapine is a leading atypical antipsychotic medication with high-affinity binding to serotonin and dopamine receptors, and unique ERK1/2 signaling effects in prefrontal cortical neurons. It is central to treatment-resistant schizophrenia research and requires careful protocol planning due to its specific pharmacology and safety profile. This article details its mechanisms, benchmarks, and workflow integration, grounded in peer-reviewed and product data.

• Haloprogin: Broad-Spectrum Antifungal Agent for Dermatophyte

  2026-05-07

  Haloprogin (1,2,4-trichloro-5-((3-iodoprop-2-yn-1-yl)oxy)benzene) stands out for its potent, quantified activity against dermatophytes, yeasts, and Gram-positive bacteria, enabling reproducible workflows in infection modeling and antifungal screening. This guide delivers actionable protocol enhancements, troubleshooting strategies, and comparative insights that leverage Haloprogin’s unique spectrum and stability profile for advanced research outcomes.

• Bufuralol Hydrochloride in β-Adrenergic Modulation Studies

  2026-05-07

  Bufuralol hydrochloride empowers advanced β-adrenergic modulation research, uniquely bridging cardiovascular pharmacology and next-generation organoid models. This guide delivers protocol clarity, troubleshooting insights, and actionable recommendations for maximizing reproducibility and translational value.

• Oral Faropenem Sodium: AMR Risks and Efficacy Insights

  2026-05-06

  This article analyzes recent findings on oral Faropenem sodium, a penem antibiotic, highlighting its therapeutic effectiveness and the risks of antimicrobial resistance (AMR) associated with its widespread use. The reference study underscores the need for responsible antibiotic stewardship to preserve carbapenem efficacy and mitigate resistance development.

• Obacunone Induces Ferroptosis in Ovarian Cancer via Akt/p53

  2026-05-06

  This study demonstrates that obacunone, a citrus-derived compound, induces ferroptosis in ovarian cancer cells by modulating the Akt/p53 signaling pathway. The research supports ferroptosis as a relevant therapeutic target in ovarian cancer and highlights the utility of selective inhibitors such as Ferrostatin-1 (Fer-1) for mechanistic studies.

• Toremifene vs Tamoxifen: Cochrane Review Insights for SERMs

  2026-05-05

  This Cochrane review rigorously compares toremifene and tamoxifen in the management of advanced breast cancer, evaluating efficacy and safety endpoints across multiple randomized trials. The findings inform selective estrogen receptor modulator (SERM) development and translational strategies in both oncology and bone health research.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

  2026-05-05

  Oliveira et al. (2025) reveal that naturally occurring angiotensin peptide fragments, including N-terminally truncated forms, significantly enhance the binding of the SARS-CoV-2 spike protein to the alternative receptor AXL. This mechanistic insight bridges cardiovascular peptide biology and viral pathogenesis, highlighting new molecular interactions with implications for both COVID-19 and blood pressure regulation research.

16105 records 1/1074 page Next 12345 下5页 Last page